[111In]-FPI-1547

N/A

Report date: 2026/01/08 20:00:10

NME

Base Information

Drug Name[111In]-FPI-1547

Drug Alias Name[111In]-FPI-1547

ClassificationRadiation-emitting products > Nuclides > Indium > 111InRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Radionuclide Drug Conjugates

Mechanisms of ActionAnti-Insulin-like growth factor I receptor

TargetsInsulin-like growth factor I receptor

Therapy Area/IndicationsUveal melanomaSolid tumoursUterine Cervical Neoplasms +[9]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited StatesAustralia

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesFusion Pharmaceuticals Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesFusion Pharmaceuticals Inc

Active IndicationsN/A

Inactive IndicationsUveal melanomaSolid tumoursUterine Cervical Neoplasms +[9]

Other Information

ATC CodeN/A